TNFRSF18 and head and neck squamous cell carcinoma: On this basis, considering the increased frequencies of NK and T cells expressing GITR, the use of agonistic GITR combined with blocking PD-1 and/or TIGIT antibodies could be beneficial in patients with HNSCC.